Related Experiment Video
Updated: May 12, 2025
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
SSRP1/SLC3A2 Axis in Arginine Transport: A New Target for Overcoming Immune Evasion and Tumor Progression in
Abstract:
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell malignancies with poor prognosis. Therefore, improved therapies are urgently required to improve patient outcomes. In this study, metabolic inhibitor drug screening reveals that quinacrine elicits excellent antitumor activity both in vitro and in vivo by downregulating intracellular arginine levels in PTCL. Single-cell transcriptomic analyses reveal aberrant arginine metabolism in patients with PTCL, characterized by excessive solute carrier family 3 member 2 (SLC3A2) mediated arginine uptake preferentially in tumor cells. High SLC3A2 expression predicts poor outcomes in PTCL, as SLC3A2-mediated arginine uptake promotes the malignant behaviors of tumor cells and induces tumor immune escape, thereby fueling tumor progression. Mechanistically, high arginine levels induce global metabolic changes, including enhanced oxidative phosphorylation by promoting nascent RNA synthesis. This work identifies structure-specific recognition protein 1 (SSRP1), which upregulates SLC3A2, as a co-transcription factor with JUNB. Quinacrine disrupts SLC3A2-mediated arginine transport by targeting SSRP1. Combining quinacrine with histone deacetylase inhibitors is a promising therapeutic strategy for PTCL.
Insights
Quinacrine, an arginine metabolism inhibitor, shows promise against Peripheral T-cell lymphoma (PTCL). By targeting arginine uptake via SLC3A2, it offers a new therapeutic strategy for this aggressive cancer.
Area of Science:
- Oncology
- Metabolic pathways
- Cancer immunology
Background:
- Peripheral T-cell lymphoma (PTCL) is a group of aggressive cancers with limited treatment options.
- Aberrant arginine metabolism is increasingly recognized as a driver of cancer progression and immune evasion.
Purpose of the Study:
- To identify novel therapeutic targets for PTCL by investigating metabolic vulnerabilities.
- To explore the role of arginine metabolism and SLC3A2 in PTCL pathogenesis and patient outcomes.
Main Methods:
- Drug screening of metabolic inhibitors, including quinacrine.
- In vitro and in vivo antitumor activity assays.
- Single-cell transcriptomic analysis to identify metabolic alterations.
- Investigation of the SLC3A2-SSRP1-JUNB axis.
Main Results:
- Quinacrine demonstrated significant antitumor activity in PTCL by reducing intracellular arginine levels.
- PTCL tumors exhibit increased arginine uptake mediated by SLC3A2, correlating with poor prognosis.
- High arginine levels promote tumor cell proliferation and immune escape through metabolic reprogramming.
- SSRP1 was identified as a key regulator of SLC3A2 expression, forming a complex with JUNB.
Conclusions:
- Targeting arginine metabolism with quinacrine represents a novel therapeutic strategy for PTCL.
- Inhibition of SLC3A2-mediated arginine uptake by quinacrine disrupts tumor progression and immune evasion.
- Combination therapy with quinacrine and histone deacetylase inhibitors shows potential for treating PTCL.
More Related Videos
10:16SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
Published on: January 6, 2017
12:58Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
Related Concept Videos
02:23Abnormal Proliferation
01:21Cell-surface Signaling